文献速递外周动脉疾病

ILLUMENATE美国关键研究与欧盟随机对照试验的四年患者水平汇总死亡率分析

Four-year patient-level pooled mortality analysis of the ILLUMENATE US Pivotal and EU randomized controlled trials.
PubMed 文献 · J Vasc Surg · 2021-09-08

该研究对ILLUMENATE美国关键试验和欧盟随机对照试验进行患者水平荟萃分析,比较Stellarex药物涂层球囊与经皮腔内血管成形术治疗股腘动脉疾病的4年全因死亡率。多因素分析显示年龄、肾功能不全和病变长度是4年死亡预测因素,而紫杉醇暴露或剂量并非预测因素。

要点

  • Stellarex DCB与PTA治疗股腘动脉疾病4年全因死亡率无显著差异。
  • 年龄、肾功能不全和病变长度是4年死亡的独立预测因素。
  • 紫杉醇暴露或剂量与4年全因死亡率无关。

核心结论

  • Stellarex药物涂层球囊与经皮腔内血管成形术治疗股腘动脉疾病在4年全因死亡率上无差异,确认了DCB可接受的长期安全性。

研究设计与样本

  • 对ILLUMENATE美国关键试验和欧盟随机对照试验进行的独立第三方患者水平荟萃分析,共纳入589例患者(DCB组419例,PTA组170例),中位随访1735天(约4.75年)。

主要发现

  • 4年总死亡81/589例(13.8%),DCB组58/419例(13.8%),PTA组23/170例(13.5%)。

临床怎么用

  • 对于股腘动脉疾病患者,Stellarex DCB的4年死亡风险与PTA相当,支持其长期安全性。
  • 应关注年龄、肾功能不全和病变长度等死亡预测因素,优化患者管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To perform a meta-analysis of two concordant randomized controlled trials (RCTs) examining the long-term, 4-year safety profile of the Stellarex drug-coated balloon (DCB) vs percutaneous transluminal angioplasty (PTA) for the treatment of peripheral artery disease. METHODS: An independent, third-party, meta-analysis of homogeneous, patient-level data from the ILLUMENATE Pivotal and ILLUMENATE EU RCTs was performed to assess mortality (time to death) in patients treated for symptomatic femoropopliteal disease. The Kaplan-Meier (KM) methodology was used to estimate hazard rates [HRs] of all-cause mortality, and Cox proportional hazard modeling was used to assess predictors of mortality. All serious adverse events, including deaths, were adjudicated by an independent, blinded clinical events committee. RESULTS: In total, 589 (419 DCB; 170 PTA) patients were included in the pooled analysis of the ILLUMENATE Pivotal and ILLUMENATE EU RCTs. The median follow-up was 1735 days (interquartile range, 1434-1829 days), equivalent to 4.75 years. Vital status compliance was >95% in each RCT. The total number of deaths through 4 years was 81 of 589 (13.8%): 58 of 419 (13.8%) in the DCB arm and 23 of 170 (13.5%) in the PTA arm. The 1-year KM estimate of all-cause mortality was 1.9% ± 0.7% (estimate ±standard error) in those treated with DCB vs 1.2% ± 0.9% in those treated with PTA. At 2, 3, and 4 years, the respective KM estimates were 6.6% ± 1.2% vs 4.9% ± 1.7%, 9.3% ± 1.4% vs 9.9% ± 2.4%, and 14.0% ± 1.7% vs 14.4% ± 2.8% (P = .864). There were no significant differences in clinical events committee-adjudicated deaths between the two cohorts. In multivariate analysis, predictors of 4-year mortality were age (HR, 1.048; 95% confidence interval [CI], 1.026-1.071; P < .0001), renal insufficiency (HR, 2.440; 95% CI, 1.566-3.800; P < .0001), and lesion length (HR, 1.004; 95% CI, 1.000-1.008; P = .041). Neither paclitaxel exposure (DCB vs PTA; HR, 1.086; 95% CI, 0.709-1.664; P = .705) nor dose (mg; HR, 1.043; 95% CI, 0.971-1.119; P = .248) was the predictor of all-cause mortality at 4 years. CONCLUSIONS: This systematic meta-analysis of two concordant ILLUMENATE RCTs shows no difference in all-cause mortality through 4 years between Stellarex DCB and PTA, confirming the acceptable, long-term safety profile of the Stellarex DCB.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lyden SP, Brodmann M, Parikh SA, et al. Four-year patient-level pooled mortality analysis of the ILLUMENATE US Pivotal and EU randomized controlled trials. J Vasc Surg. 2021. PMID: 34506898. doi:10.1016/j.jvs.2021.07.244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。